OCBC SecuritiesHomeSitemapContact Us
OCBC Investment Research
 
Parkway Holdings Limited: Fortis counters with S$3.2b offer
 
Home >> Research
Parkway Holdings Limited: Fortis counters with S$3.2b offer

By Kevin Tan
Fri, 2 Jul 2010, 08:53:55 SGT

Fortis Healthcare (through its 49%-owned RHC Healthcare) yesterday announced that it plans to make a S$3.2b voluntary conditional cash offer to acquire all the shares in Parkway at S$3.80 apiece. The offer price values Parkway at S$4.3b, and represents a 6.4% premium to its last transacted price prior to the announcement; but it is just 0.5% more than Khazanah Nasional’s partial offer price of S$3.78. We believe the offer, which is strategically priced in our view, is likely an attempt to test market’s reaction (including Khazanah’s) and to quell fears that Fortis may overpay for Parkway investment. We expect Khazanah, which reserves the right to revise the terms of its partial offer into a GO, to act along this line (especially when Fortis’ offer is just a tad above Khazanah’s), thereby starting a bidding war. Hence, while Fortis’ offer, being a GO, is more attractive than Khazanah’s, we believe shareholders should hold off acting on the offer until nearer to its closing date. Should there still be inaction on Khazanah’s part, we then advise shareholders to accept the offer.

Counterbid by Fortis. In response to Securities Industry Council regarding its intention to launch a general offer (GO) on Parkway Holdings, Fortis Healthcare (through its 49%-owned RHC Healthcare) yesterday announced that it plans to make a S$3.2b voluntary conditional cash offer to acquire all the shares in Parkway at S$3.80 apiece. The offer price values Parkway at S$4.3b, and represents a 6.4% premium to its last transacted price prior to the announcement; but it is just 0.5% more than Khazanah Nasional’s partial offer price of S$3.78.

Rationale. According to Fortis, there are significant benefits from a deeper integration between itself and Parkway, such as leveraging on combined competitive strengths and achieving operational synergies between them. We note that Fortis intends to create an integrated pan-Asian healthcare services group with Parkway as the flagship vehicle, and is considering consolidating itself into Parkway.

Condition. The offer is only conditional upon Fortis receiving valid acceptances which will result in it to hold shares carrying more than 50% of the voting rights attributable to the issued shares in Parkway. As such, shareholders have the flexibility to realize their entire investments for cash or realize part of their investments and continue to participate in the future prospects in Parkway. We understand that Fortis currently holds a 25.3% stake in Parkway, as opposed to an estimated 24.1% held by Khazanah (and related parties). As it is unlikely that the latter would accept the offer, we estimate that Fortis would require around 50% of the remaining shareholders’ acceptances (excluding Fortis and Khazanah) for the deal to go through. While Fortis reserves its right to compulsorily acquire all Parkway shares when applicable, we also note that it intends to maintain the present listing status of the group.

Our take. We believe the offer, which is strategically priced in our view, is likely an attempt to test market’s reaction (including Khazanah’s) and to quell fears that Fortis may overpay for Parkway investment. We expect Khazanah, which reserves the right to revise the terms of its partial offer into a GO, to act along this line (especially when Fortis’ offer is just a tad above Khazanah’s), thereby starting a bidding war. Hence, while Fortis’ GO offer is more attractive than Khazanah’s, we believe shareholders should hold off acting on it until nearer to its closing date. Should there still be inaction on Khazanah’s part, we would then advise shareholders to accept the offer.

 
Disclaimer for Research Report

This report is solely for information and general circulation only and may not be published, circulated, reproduced or distributed in whole or in part to any other person without our written consent. This report should not be construed as an offer or solicitation for the subscription, purchase or sale of the securities mentioned herein. Whilst we have taken all reasonable care to ensure that the information contained in this publication is not untrue or misleading at the time of publication, we cannot guarantee its accuracy or completeness, and you should not act on it without first independently verifying its contents. Any opinion or estimate contained in this report is subject to change without notice. We have not given any consideration to and we have not made any investigation of the investment objectives, financial situation or particular needs of the recipient or any class of persons, and accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of the recipient or any class of persons acting on such information or opinion or estimate. You may wish to seek advice from a financial adviser regarding the suitability of the securities mentioned herein, taking into consideration your investment objectives, financial situation or particular needs, before making a commitment to invest in the securities. OCBC Investment Research Pte Ltd, OCBC Securities Pte Ltd and their respective connected and associated corporations together with their respective directors and officers may have or take positions in the securities mentioned in this report and may also perform or seek to perform broking and other investment or securities related services for the corporations whose securities are mentioned in this report as well as other parties generally.

Privileged/Confidential information may be contained in this message. If you are not the addressee indicated in this message (or responsible for delivery of this message to such person), you may not copy or deliver this message to anyone. Opinions, conclusions and other information in this message that do not relate to the official business of my company shall not be understood as neither given nor endorsed by it.


For and on behalf of OCBC Investment Research Private Limited:

Carmen Lee
Head of Research

Co.Reg.no.:198301152E



Print  Text Size
       Download Full Report
Home | Research | Market Pulse | Technical Analysis | Strategy | IPOs & Warrants | Sector | About Us
© Copyright 2007 - OCBC Investment Research.| All Rights Reserved | Co.Reg.no.:198301152E